Company research
Affimed N.V.
CIK 1608390Updated Nov 16, 2026
SecurityAFMDQ · OTC · equity
Historical securities (1)
AFMD · NASDAQ · equity · closed May 19, 2025Name history
Affimed Therapeutics B.V. · through Sep 16, 2014
AFMDQ price & chart
Loading TradingView…
OTC:AFMDQ on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2022 · EURSource
Source
cash flow · annual statements
| Line item | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Profit or LossEUR | -15,451,000Source | -29,395,000Source | -19,409,000Source | -18,752,000Source | -12,238,000Source | -10,340,000Source | -86,004,000Source | -57,523,000Source | -41,366,000Source | -32,365,000Source |
| Additional Financial Items | ||||||||||
| AdjustmentsForIncomeTaxExpenseEUR | — | — | — | — | — | — | 2,000Source | 2,000Source | 1,000Source | 4,000Source |
| AdjustmentsForSharebasedPaymentsEUR | — | — | — | — | — | — | 19,110,000Source | 11,820,000Source | 3,381,000Source | 2,469,000Source |
| GeneralAndAdministrativeExpenseEUR | 4,036,000Source | 6,276,000Source | 8,374,000Source | 5,439,000Source | 2,606,000Source | 2,342,000Source | 32,075,000Source | 24,218,000Source | 13,715,000Source | 10,266,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | 2,000Source | 2,000Source | 1,000Source | 0Source |
| InterestPaidClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | — | — | 164,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | 1,277,000Source | 905,000Source | 78,000Source | 224,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | 564,000Source | 0Source | 294,000Source | 628,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | 733,000Source | 564,000Source | 521,000Source | 405,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | 0Source | 17,500,000Source | 0Source | 562,000Source |
| ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssetsEUR | — | — | — | — | — | — | 0Source | 0Source | 16,547,000Source | 50,945,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | 6,301,000Source | — | 0Source | 0Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | 37,000Source | 1,654,000Source | 9,000Source | 150,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | 580,000Source | 92,000Source | 2,128,000Source | 3,277,000Source |
income statement · annual statements
| Line item | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueEUR | 154,000Source | 1,390,000Source | 7,301,000Source | 9,707,000Source | 2,934,000Source | 4,008,000Source | 41,353,000Source | 40,366,000Source | 28,360,000Source | 21,391,000Source |
| Additional Financial Items | ||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | 0.3Source | 0.3Source | 0.3Source | 0.3Source |
| BasicEarningsLossPerShareEUR/shares | -1.01Source | -1.97Source | -0.13Source | -0.16Source | — | — | -0.6Source | — | — | — |
| DeferredTaxExpenseIncomeEUR | — | — | — | — | — | — | 25,022,000Source | 15,850,000Source | 11,196,000Source | — |
| DepreciationRightofuseAssetsEUR | — | — | — | — | — | — | 665,000Source | 609,000Source | 577,000Source | 384,000Source |
| DilutedEarningsLossPerShareEUR/shares | -1.01Source | -1.97Source | -0.13Source | -0.16Source | — | — | -0.6Source | — | — | — |
| EmployeeBenefitsExpenseEUR | — | — | — | — | — | — | 26,468,000Source | 20,214,000Source | 16,928,000Source | 13,207,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | 683,000Source | 3,231,000Source | 5,625,000Source | 3,586,000Source | 684,000Source | 566,000Source | 19,110,000Source | 11,820,000Source | 3,381,000Source | 2,469,000Source |
| GeneralAndAdministrativeExpenseEUR | 4,036,000Source | 6,276,000Source | 8,374,000Source | 5,439,000Source | 2,606,000Source | 2,342,000Source | 32,075,000Source | 24,218,000Source | 13,715,000Source | 10,266,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | 3,000Source | 0Source | 0Source | 0Source | 0Source | 4,000Source | 2,000Source | 2,000Source | 1,000Source | 4,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | — | — | — | — | — | — | 31,000Source | 46,000Source | 34,000Source | 24,000Source |
| OtherIncomeEUR | — | — | — | — | — | — | — | — | 626,000Source | 290,000Source |
| OtherOperatingIncomeExpenseEUR | 56,000Source | 717,000Source | 240,000Source | 332,000Source | 85,000Source | 197,000Source | 1,417,000Source | 1,310,000Source | — | — |
| ProfitLossBeforeTaxEUR | -15,448,000Source | -29,395,000Source | -19,409,000Source | -18,752,000Source | -12,238,000Source | -10,336,000Source | -86,002,000Source | -57,521,000Source | -41,365,000Source | -32,361,000Source |
| ProfitLossFromOperatingActivitiesEUR | -15,553,000Source | -29,442,000Source | -21,662,000Source | -17,200,000Source | -11,284,000Source | -9,682,000Source | -88,119,000Source | -64,030,000Source | -34,718,000Source | -32,376,000Source |
| ResearchAndDevelopmentExpenseEUR | 11,727,000Source | 25,273,000Source | 20,829,000Source | 21,800,000Source | 11,697,000Source | 11,545,000Source | 98,814,000Source | 81,488,000Source | 49,989,000Source | 43,791,000Source |